Clinical trials: Cabozantinib
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Renal cell carcinoma (RCC) is the 9th most common cancer in Australia, the 10th most common cancer in Western populations.~75% of kidney cancers are clear-cell renal cell carcinomas (ccRCC).
- Conditions
- Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma
- Trial name
- UNICAB (NCT03685448)
- Testing
- Cabozantinib
- Where
- 11 sites in Australia
- Volunteers
- 35 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes…
- Conditions
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
- Trial name
- NCT04878029
- Testing
- Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of…
- Conditions
- Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
- Trial name
- NCT03541902
- Testing
- Cabozantinib, Sunitinib Malate
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Renal Cell Carcinoma, Brain Metastases
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has…
- Trial name
- NCT06132945
- Testing
- Cabozantinib, Nivolumab, Stereotactic Radiosurgery (SRS)
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Medullary Thyroid Cancer
A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC.
- Trial name
- EXAMINER (NCT01896479)
- Testing
- Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg
- Where
- 49 sites in Australia, Canada and 12 more
- Volunteers
- 247 people
- Sponsor
- Exelixis
Lung Cancer, NSCLC Stage IV
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab).
- Conditions
- Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced NSCLC
- Trial name
- Cabatezo-1 (NCT05859217)
- Testing
- Cabozantinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jun Zhang, MD, PhD
Prostate Adenocarcinoma
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Cabozantinib (XL184) is a new drug that is being developed to treat cancer. Cabozantinib works by blocking the "angiogenesis," or the growth of new blood vessels, to the tumor.
- Trial name
- NCT01347788
- Testing
- cabozantinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Metastatic Renal Cell Carcinoma
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
This is a multicenter, open-label, exploratory, single-arm, prospective phase II study to assess the efficacy and safety profile of cabozantinib in patients with brain metastases from metastatic renal cell carcinoma (mRCC).
- Trial name
- CABRAMET (NCT03967522)
- Testing
- Cabozantinib
- Where
- 12 sites in France
- Volunteers
- 26 people
- Sponsor
- Centre Leon Berard
Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to…
- Conditions
- Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT02761057
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 595 sites in United States, Canada
- Volunteers
- 152 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
This phase II trial studies how well the combination of XL184 (cabozantinib), nivolumab, and ipilimumab work in treating patients with poorly differentiated neuroendocrine tumors (i.e., neuroendocrine tumor that does not look…
- Conditions
- Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Small Cell Neuroendocrine Carcinoma
- Trial name
- NCT04079712
- Testing
- Cabozantinib S-malate, Ipilimumab, Nivolumab
- Where
- 46 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
- Trial name
- CAROLINE (NCT04609800)
- Sponsor
- Ipsen
Hepatocellular Carcinoma, Liver Cancer
A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line Therapy
The purpose of this clinical research study is to learn about the safety and effectiveness of cabozantinib and nivolumab in people with hepatocellular carcinoma (HCC).
- Trial name
- NCT05039736
- Testing
- Cabozantinib, Nivolumab
- Sponsor
- M.D. Anderson Cancer Center
Anal Melanoma, Bladder Melanoma
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the…
- Conditions
- Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma
- Trial name
- NCT05111574
- Testing
- Biospecimen Collection, Bone Scan, Cabozantinib S-malate
- Where
- 146 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has…
- Trial name
- METEOR (NCT01865747)
- Testing
- Cabozantinib tablets, Everolimus (Afinitor) tablets
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 658 people
- Sponsor
- Exelixis
Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma
Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
This phase II trial tests how well cabozantinib in combination with pembrolizumab works in treating patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), that has spread from…
- Conditions
- Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma, Stage IV Adrenal Cortex Carcinoma AJCC v8
- Trial name
- NCT06006013
- Testing
- Pembrolizumab, Biospecimen Collection, Cabozantinib S-malate
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
This phase II clinical trial studies how well cabozantinib works in treating patients with kidney cancer before surgery. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
- Trial name
- NCT04022343
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Emory University
Cervical Cancer, Recurrent Cervical Cancer
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Drug: Cabozantinib Drug: Pembrolizumab
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer, Persistent Cervical Cancer
- Trial name
- NCT04230954
- Testing
- Cabozantinib 40 MG oral once a day, Pembrolizumab 200 mg IV every 3 weeks
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of South Alabama
Metastatic Ewing Sarcoma
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES).
- Trial name
- METTSEO (NCT07194044)
- Testing
- Vincristine, Doxorubicin, Cyclophosphamide
- Where
- 21 sites in United States
- Volunteers
- 15 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gynecologic Cancer, Carcinoma
Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
Immunotherapy has gained a significant amount of attention recently, but its efficacy as a single agent in gynecological cancers has been disappointing.
- Conditions
- Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
- Trial name
- NCT05559879
- Testing
- Cabo + Dostarlimab
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Alabama at Birmingham